$BZYR
BURZYNSKI RESEARCH INSTITUTE INC

2024 Q4 Form 10-Q Financial Statement

#000155837024013239 Filed on October 10, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $92.62K
YoY Change 143.42%
% of Gross Profit
Research & Development $277.2K
YoY Change 29.49%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $369.8K
YoY Change 46.7%
Operating Profit -$369.8K
YoY Change 46.7%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$369.8K
YoY Change 46.7%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$369.8K
YoY Change 46.7%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 131.4M 131.4M
Diluted Shares Outstanding 131.4M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.220K
YoY Change -12.86%
Cash & Equivalents $1.216K
Short-Term Investments
Other Short-Term Assets $400.00
YoY Change 0.0%
Inventory
Prepaid Expenses $400.00
Receivables
Other Receivables
Total Short-Term Assets $1.616K
YoY Change -10.07%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.616K
Total Long-Term Assets $0.00
Total Assets $1.616K
YoY Change -10.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $77.30K
YoY Change
Accrued Expenses $11.95K
YoY Change 90.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $89.25K
YoY Change 1323.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $89.25K
Total Long-Term Liabilities $0.00
Total Liabilities $89.25K
YoY Change 1322.76%
SHAREHOLDERS EQUITY
Retained Earnings -$128.8M
YoY Change 1.21%
Common Stock $128.7M
YoY Change 1.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$87.63K
YoY Change
Total Liabilities & Shareholders Equity $1.616K
YoY Change -10.07%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$369.8K
YoY Change 46.7%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$148.1K
YoY Change 23.65%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 149.0K
YoY Change 23.14%
NET CHANGE
Cash From Operating Activities -148.1K
Cash From Investing Activities
Cash From Financing Activities 149.0K
Net Change In Cash 910.0
YoY Change -26.61%
FREE CASH FLOW
Cash From Operating Activities -$148.1K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Registrant Name
EntityRegistrantName
BURZYNSKI RESEARCH INSTITUTE INC
dei Entity Central Index Key
EntityCentralIndexKey
0000724445
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--02-29
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Security Exchange Name
SecurityExchangeName
NONE
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131448444
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131448444
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-08-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-23425
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
76-0136810
dei Entity Address Address Line1
EntityAddressAddressLine1
9432 Katy Freeway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77055
dei City Area Code
CityAreaCode
713
dei Local Phone Number
LocalPhoneNumber
335-5697
dei Security12b Title
Security12bTitle
None
dei Trading Symbol
TradingSymbol
BZYR
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
131448444
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1216
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1310
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
400
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
1616
CY2024Q1 us-gaap Assets Current
AssetsCurrent
2310
CY2024Q3 us-gaap Assets
Assets
1616
CY2024Q1 us-gaap Assets
Assets
2310
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
77303
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
9010
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11947
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18423
CY2024Q3 us-gaap Liabilities
Liabilities
89250
CY2024Q1 us-gaap Liabilities
Liabilities
27433
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131448444
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131448444
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
131449
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
131449
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
128612293
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
127933634
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-128831376
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-128090206
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-87634
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-25123
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1616
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2310
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
277176
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
214057
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
92622
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38047
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
369838
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
252104
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-369838
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-252104
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-369838
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-252104
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-369838
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-252104
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131448444
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131448444
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131448444
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131448444
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
503264
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
396171
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
237906
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
143338
us-gaap Operating Expenses
OperatingExpenses
741170
us-gaap Operating Expenses
OperatingExpenses
539509
us-gaap Operating Income Loss
OperatingIncomeLoss
-741170
us-gaap Operating Income Loss
OperatingIncomeLoss
-539509
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-741170
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-539509
us-gaap Net Income Loss
NetIncomeLoss
-741170
us-gaap Net Income Loss
NetIncomeLoss
-539509
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131448444
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131448444
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131448444
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131448444
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-25123
CY2024Q2 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
58517
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
210070
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-371332
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-127868
CY2024Q3 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
149017
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
261055
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-369838
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-87634
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-13727
CY2023Q2 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
64517
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
166097
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-287405
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-70518
CY2023Q3 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
121017
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
197129
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-252104
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-4476
us-gaap Profit Loss
ProfitLoss
-741170
us-gaap Profit Loss
ProfitLoss
-539509
bzyr Clinical Trial Expenses Paid
ClinicalTrialExpensesPaid
471125
bzyr Clinical Trial Expenses Paid
ClinicalTrialExpensesPaid
363226
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-600
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-600
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
68293
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-12570
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6476
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3182
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-207628
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-185071
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
207534
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
185534
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
207534
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
185534
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-94
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
463
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1310
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
934
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1216
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1397
CY2024Q3 bzyr Ownership Interest Percentage Held By Company President And Chairman Of Board
OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard
0.810
bzyr Number Of Antineoplaston Drugs That Received Fda Approval
NumberOfAntineoplastonDrugsThatReceivedFDAApproval
0
bzyr Share Based Compensation Arrangement By Share Based Payment Award Number Of Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans
1
CY2023Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q3 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
77666
CY2023Q3 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
52942
CY2024Q3 us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
77666
CY2023Q3 us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
52942
CY2024Q3 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
8449
CY2023Q3 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
13869
CY2024Q3 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-8449
CY2023Q3 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-13869
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
155646
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
113297
us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
155646
us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
113297
us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
-13127
us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
1943
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
13127
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-1943
CY2024Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2024Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
177358
us-gaap Revenues
Revenues
0
bzyr Percentage Of Future Taxable Income Net Operating Loss Carryforwards
PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards
0.80
bzyr Percentage On Net Operating Loss Carryforwards Limit Of Taxable Income Under Coronavirus Aid Relief And Economic Security Act
PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct
0.80
bzyr Net Operating Loss Carry Forward Indefinitely
NetOperatingLossCarryForwardIndefinitely
167788
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-013239-index-headers.html Edgar Link pending
0001558370-24-013239-index.html Edgar Link pending
0001558370-24-013239.txt Edgar Link pending
0001558370-24-013239-xbrl.zip Edgar Link pending
bzyr-20240831.xsd Edgar Link pending
bzyr-20240831x10q.htm Edgar Link pending
bzyr-20240831xex31d1.htm Edgar Link pending
bzyr-20240831xex31d2.htm Edgar Link pending
bzyr-20240831xex32d1.htm Edgar Link pending
bzyr-20240831xex32d2.htm Edgar Link pending
bzyr-20240831_cal.xml Edgar Link unprocessable
bzyr-20240831x10q_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bzyr-20240831_def.xml Edgar Link unprocessable
bzyr-20240831_lab.xml Edgar Link unprocessable
bzyr-20240831_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable